Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2026

The ribonucleic acid (rna) therapy clinical trials market size has grown steadily in recent years. It will grow from $2.7 billion in 2025 to $2.83 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to limited rna-based therapeutic options, high cost of early-stage clinical trials, regulatory approval challenges, low awareness of rna therapies, reliance on traditional therapeutic modalities.

The ribonucleic acid (rna) therapy clinical trials market size is expected to see steady growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advancements in rna delivery technologies, increasing funding for rare disease and anticancer research, growing collaboration between biotech and pharma companies, rising adoption of personalized medicine approaches, expansion of global clinical trial networks. Major trends in the forecast period include increasing number of rna therapy clinical trials across therapeutic areas, growing focus on rare disease and anticancer rna therapeutics, expansion of mrna vaccine and self-amplifying rna therapy trials, adoption of crispr and rna editing-based therapy trials, integration of advanced delivery platforms and oligonucleotide conjugates.

The increasing burden of infectious diseases is expected to drive the growth of the ribonucleic acid (RNA) therapy clinical trials market in the coming years. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that invade the body, multiply, and compromise health. The rise in infectious diseases is largely fueled by increased global travel, which facilitates the rapid spread of pathogens across regions and populations. RNA therapy clinical trials aid in combating infectious diseases by supporting the development and evaluation of targeted treatments that can adapt quickly to emerging pathogens. For instance, in April 2025, the Minnesota Department of Health reported that the proportion of HIV cases among males aged 35 to 39 increased from 10% in 2023 to 17% in 2024. Therefore, the growing burden of infectious diseases is propelling the RNA therapy clinical trials market.

Key companies in this market are focusing on innovative approaches, such as RNA-based antisense oligonucleotide therapy clinical trials, which target specific genetic sequences to modulate gene expression and provide precise treatments for genetic and rare diseases. For example, in December 2024, Sepul Bio, a France-based biotechnology company, initiated the LUNA Phase 2b clinical trial to evaluate ultevursen, an RNA-based antisense oligonucleotide therapy targeting exon 13 mutations of the USH2A gene, which cause retinitis pigmentosa (RP) and Usher syndrome type 2a. This two-year, double-masked, randomized, sham-controlled study will enroll 81 adults and children aged eight and above across multiple global sites. The therapy follows promising Phase 1/2 results demonstrating improvements in visual acuity, retinal sensitivity, and retinal structure.

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma for $1 billion. Through this acquisition, Novartis strengthened its neuroscience pipeline and expanded capabilities in RNA-based therapeutics by integrating DTx Pharma’s FALCON platform and advancing small interfering RNA (siRNA) programs for neuromuscular and neurological disorders. DTx Pharma is a US-based company specializing in RNA-based therapeutics clinical trials for neuromuscular and neurological conditions.

Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.

North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ribonucleic acid (rna) therapy clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the RNA therapy clinical trials market by increasing the cost of imported nucleotides, reagents, and specialized laboratory equipment. Segments like mRNA-based vaccine trials, RNAi therapy trials, and oligonucleotide trials are most affected, particularly in North America and Europe where imports are significant. This has led to higher operational costs and potential delays in trial initiation. On the positive side, tariffs have encouraged local sourcing, investment in domestic research infrastructure, and innovation in cost-effective RNA therapy platforms.

The ribonucleic acid (rna) therapy clinical trials market research report is one of a series of new reports that provides ribonucleic acid (rna) therapy clinical trials market statistics, including ribonucleic acid (rna) therapy clinical trials industry global market size, regional shares, competitors with a ribonucleic acid (rna) therapy clinical trials market share, detailed ribonucleic acid (rna) therapy clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) therapy clinical trials industry. This ribonucleic acid (rna) therapy clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ribonucleic acid (RNA) therapy clinical trials are research studies designed to assess the safety, efficacy, and optimal use of therapies that employ RNA-based molecules to treat or prevent diseases. These trials aim to develop innovative interventions that work by modulating gene expression, correcting genetic defects, or enabling the body to produce beneficial proteins to address various medical conditions.

The main modalities in RNA therapy clinical trials include RNA interference, antisense therapy, messenger RNA (mRNA), oligonucleotides, non-antisense therapies, and non-RNA interference (RNAi) approaches. RNA interference is a natural cellular process in which small RNA molecules inhibit gene expression or translation by neutralizing specific messenger RNA molecules. These trials span multiple clinical phases, including phase I, phase II, phase III, and phase IV, and cover a wide range of therapeutic areas, such as rare diseases, anti-infectives, oncology, neurological disorders, metabolic and alimentary conditions, musculoskeletal disorders, cardiovascular and respiratory diseases, sensory disorders, and others.

The ribonucleic acid (RNA) therapy clinical trials market includes revenues earned by entities by providing services, such as RNA therapeutic administration, biological sample collection and analysis, long-term follow-up, genetic and molecular testing, and patient screening and enrollment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.